NEW YORK (GenomeWeb News) — Enigma Diagnostics yesterday said it has licensed a “broad range” of technologies from the UK’s Defense Science and Technology Laboratory that will give the company “much greater control” over IP “at the heart” of its real-time PCR systems.
 
The worldwide exclusive license covers 25 DSTL patents and patent applications. In particular, the license covers the Pyrostart, ResonSense, and Temperature Control, technologies, which Enigma called “important elements” of its RT-PCR systems.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.